Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care | Zendy

Hagen B. Huttner | Zendy; Stefan T. Gerner | Zendy; Joji B. Kuramatsu | Zendy; Stuart J. Connolly | Zendy; Jan BeyerWestendorf | Zendy; Andrew M. Demchuk | Zendy; Saskia Middeldorp | Zendy; Elena Zotova | Zendy; J. Altevers | Zendy; Frank Andersohn | Zendy; Mary J. Christoph | Zendy; Patrick Yue | Zendy; Leonhard Stross | Zendy; Stefan Schwab | Zendy

Open Access

Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

Author(s) -

Hagen B. Huttner,

Stefan T. Gerner,

Joji B. Kuramatsu,

Stuart J. Connolly,

Jan BeyerWestendorf,

Andrew M. Demchuk,

Saskia Middeldorp,

Elena Zotova,

J. Altevers,

Frank Andersohn,

Mary J. Christoph,

Patrick Yue,

Leonhard Stross,

Stefan Schwab

Publication year - 2021

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.121.034572

Subject(s) - medicine , intracerebral hemorrhage , hematoma , stroke (engine) , clinical trial , spontaneous intracerebral hemorrhage , surgery , standard of care , anesthesia , intensive care medicine , glasgow coma scale , mechanical engineering , engineering

It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, is associated with reduced hematoma expansion (HE) and mortality in patients with factor-Xa inhibitor-related intracerebral hemorrhage (ICH). We compared the occurrence of HE and clinical outcomes in patients treated either with andexanet alfa or with usual care during the acute phase of factor-Xa inhibitor-related ICH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research